trending Market Intelligence /marketintelligence/en/news-insights/trending/qke-qkjosuffm3t6ssj2bw2 content esgSubNav
In This List

Bluebird Bio closes $632.5M common stock offering

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Bluebird Bio closes $632.5M common stock offering

Bluebird Bio Inc. closed an underwritten public offering for gross proceeds of about $632.5 million.

The Cambridge, Mass.-based biotechnology company sold 3,892,308 common shares at $162.50 apiece. Shares issued include 507,692 common shares sold as part of the full exercise of the underwriters' overallotment option.

Goldman Sachs & Co. LLC, BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen acted as joint book-running managers, with Wells Fargo Securities as co-manager of the offering.

Bluebird Bio develops gene therapies for severe genetic diseases and cancer.